Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026

Phase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxAI-Designed ATR Inhibitors Advance to Preclinical Testing
/in Preclinical Research/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/in Clinical Trial, Metastatic, Phase 3/by MaxEVM16: A Personalized mRNA Cancer Vaccine Enters Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Research Unlocks Potential for Immunotherapy in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxIMGS-101: Phase 1/2 Clinical Trial Begins for Hypoxia-Reversing Agent in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxSECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 3 Trial: 225-Ac-PSMA-617 + ARPI vs SOC
/in Clinical Trial, Metastatic, Phase 3/by Max